Alnylam to Webcast Presentations at Upcoming Investor Conferences

Rhea-AI Summary

Alnylam Pharmaceuticals (Nasdaq: ALNY) will present company overviews at two virtual conferences: the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 9:40 am ET, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 2, 2021, at 10:00 am ET. Live webcasts will be available on the company's website, with replays posted within 48 hours. Alnylam is a leader in RNAi therapeutics, focusing on innovative treatments for rare and common diseases. Its product lineup includes ONPATTRO®, GIVLAARI®, and OXLUMO®.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:

• Evercore ISI 4^th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 9:40 am ET
• Piper Sandler 33^rd Annual Virtual Healthcare Conference on Thursday, December 2, 2021 at 10:00 am ET

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), and OXLUMO^® (lumasiran), as well as Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005286/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

What events will Alnylam Pharmaceuticals present at in November 2021?

Alnylam Pharmaceuticals will present at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 2, 2021.

What time will Alnylam present at the Evercore ISI HealthCONx Conference?

Alnylam will present at the Evercore ISI 4th Annual HealthCONx Conference at 9:40 am ET on November 30, 2021.

How can I listen to Alnylam's presentations at the conferences?

You can listen to Alnylam's presentations via live audio webcasts available in the Investors section of their website.

What is the focus of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapeutics, developing innovative medicines for rare genetic and complex diseases.

What products are offered by Alnylam Pharmaceuticals?

Alnylam's product lineup includes ONPATTRO®, GIVLAARI®, and OXLUMO®, with a pipeline of investigational medicines in late-stage development.